Therapy will be made at the biotech’s Philadelphia facility and a nearby CDMO, with plans to serve ‘up to several thousand patients annually’

Plus: FDA convenes panel for tofersen and updates from Blueprint, Iovance, Clinigen and more

There’s still hope for ‘not-alpha’ IL-2 therapies after Nektar’s Ph III failure, with a pipeline full of diverse modalities and MOAs

Why Neoleukin is making biologics from scratch rather than fine-tuning existing ones

How Nektar’s PEGs turned IL-2 into a viable immunotherapy partner for BMS